In vitro and in vivo data indicate that the interplay between HMOX1 and miR-378 significantly modulates NSCLC progression and angiogenesis, suggesting miR-378 as a new therapeutic target [95]. This evidence concerns the gene HMOX1 and non-small cell lung carcinoma.